Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-21. (Cancelled)

22. (Currently amended) A recombinant Fel d 1 fusion product comprising a Fel d 1 chain 1, a Fel d 1 chain 2 and a linker selected from a carbon-nitrogen bond or a peptide linker ~~having from~~ consisting of 1 to 9 amino acid residues which links the N-terminal amino acid of one chain to the C-terminal amino acid of the other chain.

23. (Previously presented) A fusion product as claimed in claim 22, wherein the linker links the N-terminal amino acid of the chain 1 to the C-terminal amino acid of the chain 2.

24. (Previously presented) A fusion product as claimed in claim 22 or 23, wherein the linker is a carbon-nitrogen bond.

25. (Currently amended) A fusion product as claimed in claim 22 or 23, wherein the short peptide ~~has from~~ consists of 1

to 5 amino acid residues and preferably from 1 to 3 amino acid residues.

26. (Previously presented) A fusion product as claimed in claim 22, wherein the linker comprises a target site for a reagent capable of selective cleavage of the linker.

27. (Previously presented) A fusion product as claimed in claim 26, wherein the reagent is an enzyme.

28. (Previously presented) A fusion product as claimed in claim 22, wherein the chain 1 and the chain 2 are covalently bonded together by one or more disulfide bridges into an antiparallel arrangement.

29. (Previously presented) A fusion product as claimed in claim 22, wherein the Fel d 1 chain 1 comprises a sequence of SEQ ID NO 1, or a homologue or fragment thereof which provides substantially the same allergenic properties as SEQ ID NO 1.

30. (Previously presented) A fusion product as claimed in claim 22, wherein the Fel d 1 chain 2 comprises a sequence of SEQ ID NO 2, SEQ ID NO 3, or a homologue or fragment thereof

which provides substantially the same allergenic properties as SEQ ID NO 2 or SEQ ID NO 3.

31. (Previously presented) A fusion product as claimed in claim 29 or 30, wherein the homologue has greater than 90% homology, preferably greater than 95% homology and particularly preferably greater than 99% homology.

32. (Previously presented) A fusion product as claimed in claim 22, comprising a sequence of SEQ ID NO 4.

33. (Previously presented) A homodimer consisting of two non-covalently associated fusion products as claimed in claim 22.

34. (Previously presented) A DNA sequence encoding the fusion product as claimed in claim 22.

35. (Previously presented) An expression vector having the DNA sequence as claimed in claim 34 inserted therein in an operable form.

36. (Previously presented) A host cell transformed with the expression vector as claimed in claim 35.

37. (Previously presented) A pharmaceutical composition comprising an immunotherapeutically effective amount of the fusion product as claimed in claim 22 and/or the homodimer as claimed in claim 33 and a pharmaceutically acceptable carrier, excipient or diluent.

38. (Previously presented) A kit for the diagnosis of cat allergy comprising the fusion product as claimed in claim 22 and/or the homodimer as claimed in claim 33 and instructions for use of the kit.

39. (Currently amended) A method for diagnosing cat allergy comprising the step of combining a sample taken from a subject with the fusion product as claimed in claim 22, ~~and/or~~ the homodimer as claimed in claim 33, or a combination thereof.

40. (Previously presented) A process for preparing a fusion product as claimed in claim 22 comprising the step of culturing the host cell as claimed in claim 36 in a suitable medium.

41. (Currently amended) A process for preparing a recombinant Fel d 1 polypeptide comprising the steps of

~~synthesising~~ synthesizing the fusion product as claimed in claims 26 or 27 and selectively cleaving the linker.